Please note: this is a draft programme and therefore subject to change.

Day 1 – Tuesday 3rd May: 12:00 – 18:00

12:00                Lunch
14:00                Welcome

The pharmacology of opioid safety
The abuse liability of maintenance medications for opioid dependence
Importance of drug interactions in treating opioid dependence in the context of HIV
Hidden risks: cardiac safety in opioid maintenance therapy
The truth of benzodiazepines
Polydrug use
Drug–drug interactions in opioid dependence – Panel Discussion

Day 2 – Wednesday 4th May: 08:45 – 17:55

Ethics in opioid pharmacotherapy: are we doing all we can to maximise safety? – Safety Workshop

SESSION 2: THE TREATMENT ARMAMENTARIUM REVISITED

Beyond methadone and buprenorphine: evaluating alternative pharmacotherapies
Improving outcomes with psychosocial interventions

SESSION 3: MAXIMISING ACCESS: MINIMISING RISKS

French solution for global export?
Office-based prescribing: the US story
Optimising outcomes with shared care
Designing opioid treatment systems to address contemporary issues
Detecting and responding to misuse and diversion
Widening access to treatment – Panel Discussion

Serious psychiatric comorbidities in opioid dependence
Clinical aspects of risk management and opioid therapy for chronic pain
ORT on Venus and Mars: gender issues in treatment
HCV and HIV in an opioid-dependent patient
Treatment through revolving doors: the recidivist patient

Day 3 –Thursday 5th May: 08:40 – 13:25

Panel discussion: Complex case study clinic

SESSION 5: CRITICAL DIFFERENCES IN THE CLINICAL CONTEXT

Critical differences in pharmacology
How to transition safely between opioids
Transition between opioids: Q&A – Panel Discussion
Maintenance or abstinence – who decides?
Personalising treatment: individualised components of treatment to optimise outcome
Best practice in treatment selection – Panel Discussion